Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Introduction: Microsatellite instability (MSI) testing and tumor mutational burden (TMB) are genomic biomarkers used to identify patients who are likely to benefit from immune checkpoint inhibitors. Pembrolizumab was recently approved by the Food and Drug Administration for use in TMB-high (TMB-H) t...

Full description

Bibliographic Details
Main Authors: Chan, N. (Author), Chan, T. (Author), de Meritens, A.B (Author), Ganesan, S. (Author), Girda, E. (Author), Groisberg, R. (Author), Jabbour, S.K (Author), Leiser, A. (Author), Malhotra, J. (Author), Mayer, T. (Author), Mehnert, J. (Author), Palmeri, M. (Author), Popli, P. (Author), Riedlinger, G. (Author), Silk, A.W (Author), Spencer, K. (Author), Stephenson, R. (Author), Subbiah, V. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
adult
Adult
biomarker
Biomarkers, Tumor
genetics
human
Humans
immune checkpoint inhibitors
immunotherapy
Immunotherapy
microsatellite instability
Microsatellite Instability
neoplasm
Neoplasms
precision medicine
Retrospective Studies
retrospective study
tumor marker
tumor mutational burden
United States
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items